PHARMA
PHARMA (30/11/2020) consolidating in ascending triangleIn H4, the stock is forming price action in ascending triangle pattern. Currently is consolidating between 5.42 and 5.80. A good entry would be after it breakout from the triangle @ EP 5.86 with Support at 5.38. TP is at 6.73 and new 52WH 8.25 (Fibo 1.272) - RRR 1:1.8
EP 5.86
TP 6.73 / 8.25
SL 5.38
Stochastic shows a pullback signal, MACD didn’t signal any breakout, and RSI didn’t show any good momentum for entry now.
PHARMA is one of market leader in Pharmaceutical sector with competitive balanced float (21% of 1440M shares) compared to its sector competitor AHEALTH (23% of 1780M shares). However, current vaccine sentiment will definitely help PHARMA in the long run.
TAYOR
Dr Reddy [Pharma Play]Stock has has been correcting for a while.
Nifty Pharma has also been correcting and could show rebound anytime soon.
Stock has taken strong support at 4800-4850 levels and has given a rebound as well.
Good time to start accumulating the stock.
MACD is has also given sign for reversal.
1st Target: 5330
2nd Target: 5500
SL@4700
Major Wave Higher? Or down we go 🎩We maybe have finished movement inside this monthly downward channel, which looks like a corrective channel for previous bullish impulse. Chances are we will go north from here. But if price will brake this channel downwards it may as well become ugly, and there is no support levels, I guess?
Anyway, now GILD highly tightened to SNP and thus electional uncertainty.
Growth potentialThe pharmaceutical sector is one of the most interesting ones in such a troubled period.
I see some growth potential for $ACAD in the short term. It is showing a positive trend that is already consolidated and heading for a possible TP of around 44-45$
I see this level as an important resistance since it has been tested repeatedly in the past.
***As usual, not a trading advice, merely my view for informational and educational purposes only***
$CLVS Triangular TIPZ close to the X'zCLOVIS maker of FDA approved Rubraca® which is a treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy. www.rubraca.com
Sitting at a pretty interesting area right now, sure it will get some more movement soon as we are at a crucial area. Plus last time I reviewed the sec docs it seemed to me like they were lowering net-losses & striving towards profits.
DYI: www.sec.gov
Divis Laboratories Sell for TGT 2850RSI Divergence on Daily Chart
Window / Gap from Rs.2784 to Rs.3063
Considering Stock has closed around Rs.3050 for 2 consecutive day, any fall from hereon would cause the stock the to fall to Rs.2784 levels.
Suggestion: Sell a Call at CMP 3050 / 3000 with a SL Rs.3120.
RLFTF - Penny Stock Heating UpAnticipating some positive news from RLFTF's and further FDA approval for it's Aviptadil.
ABCDE Triagle wave approaching completion, confirmed by Williams Alligator, and Fib Retracement
A bounced off 0.382 level
C bounced off 0.5 level
Look for E confirmation off 0.618 level
Should price exit the triangle formation, setting target @ $1.2
Pharma looks fugly on a relative basisBreaking down through support, this is what kept me out of trading PFE to the long-side even though it looked bullish. With the elections coming up and democrats leading the polls, I'd stay away from pharma and insurers. Lean towards medical devices if you need healthcare exposure.